OPZELURA
Jan 09, 2026
Vitiligo Treatment Drug Pipeline Accelerates with Late-Stage Immune-Targeting Therapies
Vitiligo represents a significant yet underrecognized health burden globally. Vitiligo, a chronic autoimmune depigmenting disorder affecting 11.7 million individuals across the leading markets in 2024, is undergoing a seismic shift in therapeutic approaches. The condition typically emerges during the second and thi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
